Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 1-Year Low – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $57.04 and last traded at $57.04, with a volume of 445 shares changing hands. The stock had previously closed at $57.28.

Analyst Ratings Changes

Separately, William Blair raised shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 7th.

Zealand Pharma A/S Stock Down 1.2%

The firm has a market cap of $3.98 billion, a P/E ratio of -22.48 and a beta of 0.74. The firm’s fifty day moving average is $65.84 and its 200 day moving average is $83.05. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $248.61 million. As a group, equities research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.